Dr. Reddy’s Launches First-to-Market Generic Bosutinib 400mg in the US

Dr. Reddy’s Laboratories has announced the first-to-market launch of Bosutinib Tablets 400mg in the United States on June 13, 2026. Developed and manufactured in collaboration with MSN Laboratories, this product is a generic equivalent of Bosulif® (bosutinib), a Tyrosine Kinase Inhibitor used in oncology. Key Deal & Product Details: Exclusivity: As a first-to-file generic, the product is eligible for 180 days of generic drug exclusivity in the US for this specific strength. Partnership Structure: MSN Laboratories handles the development and manufacturing, while Dr. Reddy’s holds the exclusive marketing rights in the US market. Market Opportunity: According to IQVIA data, the originator brand (Bosulif) generated approximately $253.8 million in US sales over the 12-month period ending April 2026, highlighting a substantial addressable market. Strategic Significance: Oncology Portfolio Expansion: Reinforces Dr. Reddy’s commitment to high-priority, complex therapies and strengthens its footprint in the lucrative US oncology segment. Patient Access: Aligns with the company's strategy to provide affordable, high-quality critical treatments to patients and healthcare providers. Revenue Visibility: The 180-day exclusivity period provides a significant window for premium pricing and margin accretion before broader generic competition enters the market. Outlook: This launch underscores Dr. Reddy's capability in executing complex generic partnerships and securing valuable exclusivity periods. The 180-day window is expected to drive strong short-term revenue contribution and solidify the company's position in the US oncology market. $DRREDDY